Medical Affairs In Early Stage Development? Seriously?

1. According to the OECD, the aging population is projected to increase global healthcare spending by many trillions of dollars in the coming decades.
2. Once the notorious killer, cardiovascular-related mortality has decreased over time—leading to an increase in prevalence of other diseases.
3. Brain disorders are expected to triple in cost to $15 trillion by 2030, and cancer cases are projected to increase by 77% by 2050 (McKinsey, WHO).
4. Healthcare systems aim to drive costs down while increasing both lifespan and health span.
5. It still costs over $2 billion to develop a new therapeutic (Deloitte).
6. 60% of launched drugs don’t hit sales forecasts, and of those that miss first-year targets, only 20% recover (ZS, Trinity, IQVIA).
7. The upcoming patent cliff may wipe $180 billion off revenue in 2027/2028 (FT/Evaluate).
8. Increasingly stringent market conditions have become the norm, with policies such as Most Favored Nation pricing, drug tariffs, and EU joint HTA.

Pharmaceutical product development is more challenging than every before. Yet, most organisations do not have Medical Affairs presence in early-stage development.  Why would you?   Most organisations involve Medical Affairs at Phase 3 before pivotal trial read-out.  This is already late if we consider the challenges affecting drug development and chances of launch success.  Involving Medical Affairs early already may increase chances of progressing programmes to filing as well as increasing chances of a successful launch and return on investment.  

Join our experts who will be covering the burning platform that is early stage drug development, listen and ask them questions on their thoughts on the role of Medical Affairs in early-stage drug development.

Learning Objectives

1. Understand the benefits and opportunities of involving Medical Affairs in early therapeutic development stages.
2. Learn how a robust Medical Affairs function can shape development strategy and support launch readiness.
3. Define the ideal role Medical Affairs should play in early product development.

Speakers: